Form 4: Prelude Therapeutics Inc. Executive Granted Stock Options
SEC Form 4 Filing
Bryant David Lim, Chief Legal Officer and Corporate Secretary of Prelude Therapeutics Inc., was granted stock options for 150,000 shares on March 1, 2024.
Summary
- Bryant David Lim, the Chief Legal Officer and Corporate Secretary of Prelude Therapeutics Inc., was granted stock options on March 1, 2024.
- The options are for 150,000 shares of Prelude Therapeutics Inc. common stock.
- The exercise price of the options is $4.59 per share.
- The options vest as to 25% on March 1, 2025, and then monthly at a rate of 1/48 of the total shares until fully vested, contingent upon continued service to the Issuer.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive and the company's future performance. However, it's not a major event that would drastically alter investor sentiment.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the executive, aligning their interests with the company's performance over several years.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and retention.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns executive interests with long-term company performance.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | Date of transaction: Grant of stock options for 150,000 shares. |
| 03/01/2025 | First vesting date: 25% of the stock options vest. |
| 02/28/2034 | Expiration date of the stock options. |
| 03/04/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.